Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine
I last wrote here several months ago about the sodium channel (NaV1.8) inhibitor VX-548 (now known as suzetrigine), which is ...
AFP1d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Obsidian Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...
Boston commercial real estate hoped for a rebound in 2024. It never came.
More downtown commercial landlords challenged the city’s assessment of their building values, though Boston tax officials ...
Most notable Massachusetts drug approvals of 2024
The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...
Wall Street Journal15d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Hosted on MSN19d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
The Motley Fool19d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...
Insider Monkey21d
Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks that will make you rich in 2025. Jurrien Timmer, Director of ...
bovnews21d
Vertex Pharmaceuticals Inc (VRTX) Stock: Analyzing Its Quiet Power
H.C. Wainwright has recently reiterated Vertex Pharmaceuticals Inc (VRTX) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on December 19, 2024, Oppenheimer had ...